Status
Conditions
Treatments
About
The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.
Full description
This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the consecutive days, once daily.
Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin for 3 consecutive days. The standard arterial canula will be used to obtain samples.
30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.
Serum caspofungin concentration will be measured with high performance liquid chromatography.
Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
33 participants in 1 patient group
Loading...
Central trial contact
Mirosław Czuczwar, M.D., PhD; Michał Borys, M.D., PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal